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Background 
Cancer is characterized by uncontrolled and invasive growth of cells 
(metastasis) 
 The second ranking cause of death in the industrialized world 
 
Conventional anticancer therapies  
 surgical resection, radiotherapy and chemotherapy 
 ineffective (about half of cancer sufferers) 
 alternative techniques are being developed 
 
Experimental cancer treatments 
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Experimental cancer treatments 
Improving, supplementing or replacing conventional methods 
 
 Photodynamic therapy 
 HAMLET (human alpha lactalbumin made lethal to tumor cells) 
 Gene therapy 
 Telomerase therapy 
 Hyperthermia therapy 
 Dichloroacetate (DCA) 
 Diet therapy 
 Insulin potentiating therapy  
 Bacterial treatment 
 
Many of these therapies are controversial due to lack of evidence, 
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Bacterial therapy 
The first scientifically-observed treatment dates back to the Nineteenth century 
 Busch  (1868)  
 Certain types of cancers regressed following accidental erysipelas 
(Streptococcus pyogenes) infections 
 William Coley (1991)  
 The patient with neck cancer began to recover following an infection with 
erysipelas 
 Coley's toxins (a safer vaccine) 
 a mixture of inactivated S. pyogenes and Serratia marcescens 
 sarcomas, carcinomas, lymphomas, melanomas and myelomas 
 Certain species of anaerobic bacteria (the genus Clostridium)  
 Thrive and consume oxygen-poor cancerous tissue 
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1. Bacteria as tumoricidal agents 
2. Bacteria as vector for gene therapy 
3. Bacterial toxins for cancer treatment 
4. Bacteria as immunotherapeutic agents 
5. Bacterial spores 
 
Advantageous features such as capacity to simultaneously carry 
and express multiple therapeutic proteins, and elimination by 
antibiotics 
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Bacteria as tumoricidal agents 
live, attenuated )genetically-modified(, nonpathogenic bacteria 
1. To provide direct tumoricidal effects  
2. To deliver tumoricidal molecules 
 
The potential to target and colonize solid tumors could be shown for many different 
bacteria  
 Obligate anaerobic bacteria like Clostridia or Bifidobacteria 
 Facultative anaerobic bacteria like Salmonellae or E. coli 
)The hypoxic conditions that are found in necrotic areas of solid tumors( 
 
 The major problem with using bacteria as anti-cancer agents is 
their toxicity at the dose required for therapeutic efficacy 
 Restrict to preclinical animal models 
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Live bacterial anti-tumor agents 
 
Bacillus Calmette-Guerin (BCG) 
 A derivative of Mycobacterium bovis (vaccine strain against tuberculosis) 
 In 1950s BCG was studied as an anticancer agent 
 BCG plus TURBT the most successful treatment 
 Immunotherapy: induces complex immune response 
 Dramatically decreases the recurrence rates in 70% of the patients 
 Instillation of BCG directly to tumor site (2-3 weeks after surgery)  
 Once a week for 6 weeks 
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Bacteria as vector for gene therapy 
 The specific targeting of therapy directly to a solid tumor 
 The use of bacteria, genetically engineered to express a specific therapeutic 
gene 
 Bacterial vectors can provide a powerful adjuvant therapy to various cancer 
treatments 
 As vectors for delivering: 
 anticancer agents 
 cytotoxic peptides 
 therapeutic proteins to solid tumors 
 
 A mutant of S. typhimurium, has been engineered to express interleukin-2 
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Bacterial spores 
 The spores of anaerobic bacteria 
 The spores can germinate in the 
dead areas inside tumors 
 Spores of genetically modified 
strain C. novyi 
 No clinical toxicity was observed 
in healthy mice or rabbits 
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Bacterial toxins for cancer treatment 
 Diphtheria toxin (DT) 
 Pseudomonas exotoxin A (PE) 
 Clostridium perfringes type A enterotoxin (CPE) 
 Anthrax toxin  
 
 The most potent cell-killing agents 
 Need to be targeted to specific sites on the surface of cancer cells 
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Bacterial toxins for cancer treatment 
(Kabat, Iglewski, et al.)  
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Design of toxins as anti-cancer agents 
(immunotoxins) 
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Tumor cell cytotoxicity 
 A-B structure  
 B-domain: interaction with receptors  
 A-domain: toxic domain 
 Recombinant  immunotoxins: A toxic domain fused to  
 monoclonal antibodies 
 antibody fragments 
 ligands like cytokines and growth factors 
 Clinical trials: performed with positive results in leukemia and bladder cancer 
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Bacterial toxins for cancer treatment 
Clostridium perfringes type A enterotoxin (CPE) 
 The causative agent of gastroenteritis 
 The C terminal: binding to the CPE receptor (CPE-R) 
 The N-terminal: cytotoxicity  
 Purified CPE: an acute cytotoxic effect on pancreatic cancer cells    
(tumor necrosis and inhibition of tumor growth in vivo) 
 Claudin-3 &4 are the specific receptors for CPE: are abundantly expressed 
in ovarian, breast, uterine, and pancreatic cancers  
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Bacterial toxins for cancer treatment 
Anthrax toxin 
 Harry Smith in 1954 
 The major virulence factor of Bacillus anthracis 
 Aerobic, facultative anaerobic, spore-forming, nonmotile, nonhemolytic gram-
positive rods 
 Key virulence genes are found on plasmids pXO1 and pXO2  
 pXO1: the structural genes for the anthrax toxin proteins 
 pXO2: carries three genes required for capsule synthesis (poly-D-glutamic acid) 
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Anthrax toxin 
 Consists of three individually non-toxic proteins (A-B Toxin) 
 Assemble at the mammalian cell surface into toxic complexes 
Protective Antigen (PA) 
 83-kDa (63 , 20-kDa)   
 Ability to elicit a protective immune response against anthrax  
 Common cell binding domain (B) 
 forms an oligomeric translocase channel 
 delivers the two enzyme components 
Edema Factor (EF)  
 89-kDa 
 adenylate cyclase (calmodulin dependence)    cAMP 
 EF plus PA creates edema toxin (ET) 
Lethal Factor (LF) 
 90-kDa 
 zinc-dependent    protease cleaves MAPKKs     apoptosis 
 LF plus PA creates lethal toxin (LT) 
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Pathogenesis 
 Cutaneous – gastrointestinal - inhalation (deadliest form) 
 
 The spores are taken up in macrophages  
 Macrophages are then transported to the lymph nodes 
 The spores enter the vegetative state in the macrophages 
 The infected macrophages lyse and bacteria are released into the blood 
stream 
 Virulence factors help the bacteria to evade the host’s immune system 
 Death from virulent B. anthracis is due to the production of a toxin that 
shuts down the host’s immune system and causes cell death 
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Anthrax Toxin Mechanism 
1. Binding of PA to a cell surface receptor 
 Receptors: TEM-8 (ANTXR1) and CMG-2 (ANTXR2) 
2. Receptor-bound PA is cleaved into two fragments by a furin family 
protease (Dissociation of the smaller fragment) 
3. The receptor-bound carboxyl-terminal 63-kDa fragment (PA63) to 
form a ring-shaped heptamer (lipid rafts) 
4. The oligomerization of PA63 provides the binding site for LF and EF 
5. The resulting complexes are endocytosed to an acidic compartment 
6. In acidic endosomes, the complex forms pores through which lethal 
factor reaches the cytosol 
7. EF or LF gets injected into the cytosol of the cell 
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Anthrax Toxin Mechanism 
Edema Toxin 
 A Ca2+, calmodulin-dependent adenylate cyclase 
 catalyzes the conversion of ATP to cyclic AMP (cAMP) 
1. An increase in the amount of cAMP causes the cell to swell 
 cAMP is an important regulatory molecule (maintain proper 
osmotic pressure by regulating the flow of small ions and water in 
and out of the cell) 
2. A decrease ATP (Macrophages need the energy/infected macrophages 
become useless) 
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Anthrax Toxin Mechanism 
Lethal Toxin 
 A zinc protease 
 Targets members of the mitogen-activated protein kinase kinase 
(MAPKK) family 
 Leads to inhibition of several cell signaling pathways  
 An increased amount of cytokines, protein that act as cell mediators 
 High cytokine levels cause an increase in harmful oxidative molecules. 
If the concentration of these harmful molecules gets too high within the 
cell, the macrophage ruptures and dies 
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Anti- Angiogenic And Tumoricidal effects of  
Anthrax Toxin 
Prerequisite for invasive growth and metastatic spread of tumors: 
1. Angiogenesis (The growth of new blood vessels) 
 Inhibition of angiogenesis is an important strategy for current anti-
cancer therapies 
 TEM-8 and CMG-2 (anthrax receptors) :  
 In epithelia lining of skin, lung, and small intestine (in normal) 
 overexpressed during angiogenesis 
 Functional roles in angiogenesis: 
 TEM-8: to regulate endothelial cell migration and tubule formation 
 CMG-2: endothelial proliferation 
 
CMG-2 and TEM-8 are potential targets for anti- angiogenic therapy 
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Anti- Angiogenic And Tumoricidal effects of  
Anthrax Toxin 
 Anti-angiogenic effects of anthrax toxin: 
LT (MAPK inhibition) and ET (    cAMP) 
 The unique requirement of PA to make its activation 
 provides an opportunity to re-engineer this protein 
 A number of mutations to PA increase its selectivity and targeting of 
tumor cells 
replacing the furin activation site on a recombinant anthrax toxin 
with a Urokinase plasminogen activator (uPA) activation site. 
 uPA are overexpressed in human tumors   of: 
   colon cancer, breast cancer, bladder cancer, thyroid cancer, liver     
cancer, pleura cancer, lung cancer, pancreas cancer, ovaries 
cancer, and the head and neck cancer 
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Anti- Angiogenic And Tumoricidal effects of  
Anthrax Toxin 
2. Dissolution of the extracellular matrix 
 serine, metallo-, and cysteine proteases 
 uPA:  
 serine protease 
 overexpressed in a variety of human cancers 
 The active uPA/uPAR complex cleaves plasminogen into plasmin 
 Absent on normal cells (wound healing) 
Take advantages of 
 The expression of the urokinase system on tumor 
 The obligatory requirement for proteolytic processing of PA 
 To target uPA-expressing tumor cells with modified anthrax toxin   
 The native furin cleavage site was replaced by a uPA cleavage 
23 by: Mohammad Sekhavati /                                    
Dr. M. Aslanimehr 
 24 by: Mohammad Sekhavati /                                    
Dr. M. Aslanimehr 
Related Studies 
 In 1976: Discovery that uPA is produced and released from cancer cells 
(roles in the metastasis of human tumors) 
 Serve as targets for novel cancer  
 Interfering with uPA (antibodies, inhibitors, and synthetic uPA analogues) 
 Only the progression of tumors get slow without a cytotoxic action 
 
 In 2001, Liu:  to exploit the protease activity of uPA to target cytotoxic 
bacterial toxin fusion proteins to tumor  cells 
 PA/FP59: mutated anthrax toxin-protective antigen fused to the 
Pseudomonas exotoxin A (FP59) 
 Treatment of tumor cells (HeLa cells, human melanoma A2058 cells)  with  
PA/FP59 
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Thanks for your attention 
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The man who makes no 
mistake, 
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